Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

9.990 -0.040 (-0.40%)
Streaming Delayed Price Updated: 3:20 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zenas BioPharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026. 
Via Benzinga
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
From Zenas BioPharma
Via GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
StandardAero Surges In Market Debut
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
Via Talk Markets
Topics Initial Public Offering
Week In Review: Zenas Raises $259 Million In IPO
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
From Zenas BioPharma
Via GlobeNewswire
Trio Of Biotech IPOs Climb In Debut
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
Via Talk Markets
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.